{"id":"semaglutide-treatment","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"20–30","effect":"Diarrhea"},{"rate":"15–25","effect":"Constipation"},{"rate":"10–20","effect":"Abdominal pain"},{"rate":"5–10","effect":"Hypoglycemia (when combined with insulin or sulfonylureas)"}]},"_chembl":{"chemblId":"CHEMBL4752331","moleculeType":"Unknown","molecularWeight":"4113.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1. It stimulates pancreatic beta cells to release insulin in response to elevated blood glucose, delays stomach emptying to reduce postprandial glucose spikes, and acts on the brain to suppress appetite and increase satiety. These combined effects result in improved glycemic control and significant weight loss.","oneSentence":"Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:24.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Chronic weight management in adults with obesity or overweight with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT07478653","phase":"NA","title":"MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease","status":"NOT_YET_RECRUITING","sponsor":"Oelisoa Andriankaja","startDate":"2026-05-01","conditions":"Obesity, Dental Care for Children","enrollment":50},{"nctId":"NCT06751589","phase":"EARLY_PHASE1","title":"A Study of a Weight Loss Intervention in People With Endometrial Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-19","conditions":"Endometrial Cancer","enrollment":36},{"nctId":"NCT07361874","phase":"NA","title":"IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-03-05","conditions":"Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's","enrollment":75},{"nctId":"NCT07446998","phase":"PHASE2","title":"Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","status":"RECRUITING","sponsor":"Veru Inc.","startDate":"2026-03","conditions":"Obesity & Overweight, Mobility Disability, HOMA-IR","enrollment":200},{"nctId":"NCT06222437","phase":"PHASE1","title":"Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy","status":"WITHDRAWN","sponsor":"Methodist Health System","startDate":"2026-02","conditions":"Polycystic Ovary Syndrome","enrollment":""},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT07487103","phase":"PHASE3","title":"Efficacy and Safety of QLG1090 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04-01","conditions":"Type 2 Diabetes","enrollment":478},{"nctId":"NCT07485062","phase":"PHASE4","title":"Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-05-01","conditions":"Type 2 Diabetes, Cognitive Decline in Older Adults","enrollment":164},{"nctId":"NCT07227948","phase":"PHASE2","title":"Repurposing Semaglutide for the Treatment of Cocaine Use Disorder","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2026-01-15","conditions":"Cocaine Use Disorder","enrollment":75},{"nctId":"NCT07107334","phase":"PHASE2","title":"A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-03","conditions":"Endometrioid Endometrial Adenocarcinoma","enrollment":20},{"nctId":"NCT07216651","phase":"","title":"WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults","status":"COMPLETED","sponsor":"Closed Loop Medicine","startDate":"2025-09-23","conditions":"Obesity & Overweight","enrollment":20},{"nctId":"NCT06989177","phase":"NA","title":"Probiotic Intervention on Body Weight","status":"RECRUITING","sponsor":"Chinese Academy of Sciences","startDate":"2025-06-10","conditions":"Obesity, Homeostasis, Weight Loss","enrollment":140},{"nctId":"NCT07207148","phase":"","title":"People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-11-15","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT07195994","phase":"NA","title":"A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes","status":"RECRUITING","sponsor":"QuickSilver Scientific","startDate":"2026-02-05","conditions":"Prediabetes / Type 2 Diabetes","enrollment":90},{"nctId":"NCT06762314","phase":"PHASE2","title":"Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-01-20","conditions":"Diabetes","enrollment":105},{"nctId":"NCT07466017","phase":"PHASE2","title":"A Study of CS060380 Tablets in Patients With MASH and Obesity","status":"NOT_YET_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2026-04-14","conditions":"Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity","enrollment":120},{"nctId":"NCT07112872","phase":"PHASE2","title":"A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-08-19","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT07465965","phase":"PHASE1","title":"A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults","status":"RECRUITING","sponsor":"Shanghai World Leader Pharmaceutical Co., Ltd.","startDate":"2026-03-02","conditions":"Overweight, Obesity","enrollment":60},{"nctId":"NCT07213466","phase":"PHASE4","title":"Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-19","conditions":"Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder","enrollment":100},{"nctId":"NCT05649137","phase":"PHASE3","title":"A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-04","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":512},{"nctId":"NCT04596631","phase":"PHASE3","title":"A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-02","conditions":"Diabetes Mellitus, Type 2","enrollment":132},{"nctId":"NCT03811561","phase":"PHASE3","title":"A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-05-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1500},{"nctId":"NCT07249554","phase":"PHASE2","title":"Combination Therapy for Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-05","conditions":"Alcohol Use Disorder","enrollment":45},{"nctId":"NCT06975111","phase":"PHASE2, PHASE3","title":"Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-03-01","conditions":"Menopause, Menopause Hot Flashes, Menopause Related Conditions","enrollment":200},{"nctId":"NCT07457424","phase":"","title":"Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College Dublin","startDate":"2022-02-17","conditions":"Metabolic Disease, Obesity & Overweight","enrollment":140},{"nctId":"NCT05371496","phase":"PHASE2","title":"Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2022-09-06","conditions":"Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity","enrollment":81},{"nctId":"NCT05254314","phase":"PHASE2","title":"Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-10-11","conditions":"Asthma","enrollment":100},{"nctId":"NCT07055607","phase":"","title":"A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2025-11-21","conditions":"Obesity","enrollment":1250},{"nctId":"NCT06885736","phase":"NA","title":"LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy","status":"NOT_YET_RECRUITING","sponsor":"Dasman Diabetes Institute","startDate":"2026-03-10","conditions":"Obesity","enrollment":232},{"nctId":"NCT07446439","phase":"PHASE3","title":"A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use","status":"NOT_YET_RECRUITING","sponsor":"Vanda Pharmaceuticals","startDate":"2026-02-25","conditions":"Nausea and Vomiting, Obesity","enrollment":280},{"nctId":"NCT06897475","phase":"PHASE2","title":"A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-28","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT07444073","phase":"","title":"Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock","status":"NOT_YET_RECRUITING","sponsor":"National University of Singapore","startDate":"2026-02-02","conditions":"Aging, Obesity & Overweight","enrollment":440},{"nctId":"NCT06027567","phase":"PHASE4","title":"The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure","status":"COMPLETED","sponsor":"Rigmor Højland Jensen","startDate":"2022-09-02","conditions":"Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity","enrollment":38},{"nctId":"NCT07285902","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2025-12-25","conditions":"Obesity","enrollment":572},{"nctId":"NCT07172867","phase":"PHASE2","title":"A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM","status":"WITHDRAWN","sponsor":"Halia Therapeutics, Inc.","startDate":"2026-01-06","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":""},{"nctId":"NCT06546384","phase":"NA","title":"GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","status":"NOT_YET_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2026-05-01","conditions":"Adiposity, Fatty Liver, Alcohol Use Disorder","enrollment":64},{"nctId":"NCT07430059","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant","status":"NOT_YET_RECRUITING","sponsor":"Vivani Medical, Inc","startDate":"2026-04","conditions":"Obesity & Overweight","enrollment":20},{"nctId":"NCT07428746","phase":"PHASE3","title":"Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-04","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT05891496","phase":"PHASE3","title":"A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-06-20","conditions":"Alzheimers Disease","enrollment":23},{"nctId":"NCT07430332","phase":"PHASE2","title":"GLP-1 RA for Stage 1 Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2027-09-01","conditions":"Stage 1 Diabetes Mellitus, Type 1","enrollment":15},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT06015893","phase":"PHASE2","title":"Semaglutide Therapy for Alcohol Reduction (STAR)","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-10-17","conditions":"Addiction, Alcohol Use Disorder","enrollment":52},{"nctId":"NCT06184568","phase":"PHASE3","title":"A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2024-02-29","conditions":"Type 2 Diabetes, Obesity","enrollment":349},{"nctId":"NCT07417618","phase":"","title":"INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-01-27","conditions":"Type 2 Diabetes, Overweight, ASCVD","enrollment":60000},{"nctId":"NCT07280403","phase":"NA","title":"Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss","status":"COMPLETED","sponsor":"INQUIS Clinical Research","startDate":"2024-09-12","conditions":"Weight Loss","enrollment":60},{"nctId":"NCT07101939","phase":"PHASE2","title":"A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)","status":"RECRUITING","sponsor":"Actimed Therapeutics Ltd","startDate":"2025-06-23","conditions":"Obesity, Muscle Loss","enrollment":120},{"nctId":"NCT07411378","phase":"PHASE2","title":"Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.","status":"NOT_YET_RECRUITING","sponsor":"Biophytis","startDate":"2026-07","conditions":"Muscle Wasting, Obesity & Overweight, Obesity","enrollment":164},{"nctId":"NCT07294950","phase":"PHASE3","title":"Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination","status":"RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2026-02-01","conditions":"Obesity (Disorder), Weight Change, Blood Pressure Monitoring","enrollment":98},{"nctId":"NCT06478550","phase":"","title":"A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-06-26","conditions":"Diabetes Mellitus, Type 2","enrollment":304},{"nctId":"NCT07401992","phase":"PHASE4","title":"Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2026-01-15","conditions":"Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2","enrollment":62},{"nctId":"NCT06173778","phase":"PHASE2","title":"Semaglutide for Post-Smoking Cessation Weight Management","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2024-04-23","conditions":"Obesity, Overweight, Cigarette Smoking","enrollment":197},{"nctId":"NCT07389941","phase":"PHASE4","title":"Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"University of Luebeck","startDate":"2026-10","conditions":"Atrial Fibrillation (AF)","enrollment":240},{"nctId":"NCT04972721","phase":"","title":"SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-01","conditions":"Overweight, Obesity","enrollment":3439},{"nctId":"NCT06977438","phase":"PHASE4","title":"Promoting Healthy Children and Youth","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2027-01-01","conditions":"Obesity, Childhood","enrollment":1020},{"nctId":"NCT07392151","phase":"PHASE3","title":"Reversal to Normoglycemia by Treating Prediabetes","status":"NOT_YET_RECRUITING","sponsor":"Michael Mæng","startDate":"2026-02","conditions":"Prediabetes, Chronic Coronary Syndrome","enrollment":158},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT03498001","phase":"NA","title":"Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2018-04-16","conditions":"Type II Diabetes","enrollment":42},{"nctId":"NCT07223983","phase":"PHASE1","title":"Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Alcohol Use Disorder, Weight Loss, Bariatric Surgery Patients","enrollment":10},{"nctId":"NCT07202247","phase":"PHASE2","title":"Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-01-23","conditions":"Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":60},{"nctId":"NCT07187830","phase":"","title":"Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-02-15","conditions":"Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight","enrollment":52},{"nctId":"NCT07382388","phase":"","title":"A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2026-01-28","conditions":"Psoriasis","enrollment":70},{"nctId":"NCT06467604","phase":"","title":"CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2024-11-01","conditions":"Obesity","enrollment":7},{"nctId":"NCT05202353","phase":"PHASE1","title":"A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-10-01","conditions":"Obesity","enrollment":30},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT06221969","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-01-16","conditions":"Type 2 Diabetes","enrollment":1000},{"nctId":"NCT06605703","phase":"PHASE4","title":"A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"WW International Inc","startDate":"2024-09-18","conditions":"Obesity, Overweight","enrollment":226},{"nctId":"NCT07081178","phase":"","title":"A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2025-08-08","conditions":"Obesity","enrollment":555},{"nctId":"NCT07141914","phase":"","title":"A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2025-08-29","conditions":"Overweight, Obesity, Heart Failure (HF)","enrollment":285327},{"nctId":"NCT07225816","phase":"PHASE1","title":"Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-11-07","conditions":"Obesity","enrollment":75},{"nctId":"NCT06390501","phase":"NA","title":"The Effect of Weekly Semaglutide Treatment on Energy Expenditure","status":"COMPLETED","sponsor":"Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences","startDate":"2024-04-01","conditions":"Obesity; Drug","enrollment":60},{"nctId":"NCT06065540","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-27","conditions":"Type 2 Diabetes Mellitus","enrollment":2734},{"nctId":"NCT05788965","phase":"PHASE2, PHASE3","title":"Semaglutide in CFRD","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-10-16","conditions":"Cystic Fibrosis, Cystic Fibrosis-related Diabetes","enrollment":8},{"nctId":"NCT07242534","phase":"PHASE4","title":"Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.","status":"RECRUITING","sponsor":"Fundacion Dexeus","startDate":"2026-01-19","conditions":"Infertility, Obesity","enrollment":62},{"nctId":"NCT07336862","phase":"PHASE1, PHASE2","title":"Bariatric Surgery Combined With GLP-1 Receptor Agonists Study","status":"RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2024-01-01","conditions":"Obesity","enrollment":200},{"nctId":"NCT06500143","phase":"","title":"Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2024-10-09","conditions":"Gastric Retention","enrollment":94},{"nctId":"NCT05984238","phase":"NA","title":"A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-08-03","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT06852391","phase":"PHASE4","title":"JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-18","conditions":"Obesity (Disorder)","enrollment":74},{"nctId":"NCT06577090","phase":"PHASE2","title":"Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Skye Bioscience, Inc.","startDate":"2024-08-22","conditions":"Obesity","enrollment":136},{"nctId":"NCT06323174","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-19","conditions":"Type 2 Diabetes","enrollment":189},{"nctId":"NCT05872022","phase":"","title":"A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2023-07-05","conditions":"Pregnancy, Obesity, Overweight","enrollment":728},{"nctId":"NCT06579105","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-08","conditions":"Diabetes Mellitus, Type 2","enrollment":406},{"nctId":"NCT06042153","phase":"PHASE4","title":"DIALYSIS-TIR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-12-05","conditions":"Type 2 Diabetes, End Stage Renal Disease on Dialysis","enrollment":43},{"nctId":"NCT06648031","phase":"PHASE1","title":"Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants","status":"COMPLETED","sponsor":"Lexaria Bioscience Corp.","startDate":"2024-12-04","conditions":"Type2diabetes","enrollment":148},{"nctId":"NCT06903923","phase":"","title":"Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2025-06-01","conditions":"Obesity in Children, Bone Strength, GLP - 1","enrollment":120},{"nctId":"NCT06207877","phase":"PHASE1","title":"A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-23","conditions":"Obesity","enrollment":62},{"nctId":"NCT07302802","phase":"","title":"Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice","status":"RECRUITING","sponsor":"Prof. Dr. Martin Wabitsch","startDate":"2025-12-01","conditions":"Monogenic Obesity","enrollment":70},{"nctId":"NCT06267092","phase":"PHASE1","title":"A Study of How CagriSema Works on Appetite in People With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-15","conditions":"Overweight, Obesity","enrollment":164},{"nctId":"NCT07319975","phase":"NA","title":"Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity","status":"NOT_YET_RECRUITING","sponsor":"Istanbul Galata University","startDate":"2025-12-29","conditions":"Obesity","enrollment":48},{"nctId":"NCT07314684","phase":"PHASE4","title":"GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-09-08","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":80},{"nctId":"NCT04469855","phase":"","title":"Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-07-27","conditions":"Diabetes Mellitus, Type 2","enrollment":3217},{"nctId":"NCT05443191","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-10-20","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT06507475","phase":"","title":"Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-09-07","conditions":"Diabetes Mellitus, Type 2","enrollment":209},{"nctId":"NCT05702931","phase":"PHASE4","title":"Semaglutide Treatment for Hyperglycaemia After Renal Transplantation","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-09-19","conditions":"Hyperglycemia, Renal Transplant Complication Primary Non-Function, Diabetes","enrollment":104},{"nctId":"NCT06801015","phase":"PHASE4","title":"Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-10-01","conditions":"Obesity","enrollment":30},{"nctId":"NCT06640972","phase":"PHASE2","title":"Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists","status":"COMPLETED","sponsor":"Response Pharmaceuticals","startDate":"2024-09-27","conditions":"Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated","enrollment":68},{"nctId":"NCT04982575","phase":"PHASE2","title":"Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-08-02","conditions":"Diabetes Mellitus, Type 2","enrollment":92},{"nctId":"NCT07058155","phase":"PHASE4","title":"Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-12-17","conditions":"Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity","enrollment":70},{"nctId":"NCT07297238","phase":"NA","title":"Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.","status":"NOT_YET_RECRUITING","sponsor":"Jinling Hospital, China","startDate":"2026-01-01","conditions":"Short Bowel Syndrome (SBS), Intestinal Failure","enrollment":20},{"nctId":"NCT06954090","phase":"PHASE4","title":"Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study","status":"ENROLLING_BY_INVITATION","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2025-11-20","conditions":"Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":293,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Semaglutide Treatment","genericName":"Semaglutide Treatment","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}